Korro Bio, Inc.
KRROHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKorro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent. Valued at $172.5M, KRRO is a micro-cap name in its sector. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Market Cap
$172.5M
Beta
2.11
P/E (TTM)
—
P/E (Fwd)
-2.37
EPS (TTM)
$-12.08
EPS (Fwd)
$-5.04
ROE
-87.8%
ROA
-26.8%
Cash
$114.0M
Total Debt
$42.9M
Free CF
-$39.0M
52W Change
-15.7%
Annual Financials
Cash vs Debt
Where KRRO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, KRRO finished 16.30% above its 150-day moving average ($11.41) and 17.93% below its 200-day moving average ($16.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KRRO overbought or oversold?
At the July 15, 2026 close, KRRO's RSI(14) was 46.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $114.0M in cash and $42.9M in debt, KRRO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$39.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -87.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Korro Bio, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, KRRO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing KRRO.